Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

Clinical trial NCT00077675 · COMPLETED

Trial details

NCT number: NCT00077675
Sponsor: Cumberland Pharmaceuticals
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Infections, Gram-positive Bacterial

Start date: 2004-02-01
Primary completion: 2004-09-01
Enrollment: 201

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.